Gilead Sciences, Inc. (GILD)
166.89
-0.68
(-0.41%)
USD |
NASDAQ |
Nov 06, 16:00
166.00
-0.89
(-0.53%)
After-Hours: 20:00
Gilead Sciences Cash from Investing (Quarterly) : -244.00M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -244.00M |
| June 30, 2026 | -10.35B |
| March 31, 2026 | 1.77B |
| December 31, 2025 | -1.835B |
| September 30, 2025 | -427.00M |
| June 30, 2025 | -2.116B |
| March 31, 2025 | -415.00M |
| December 31, 2024 | -225.00M |
| September 30, 2024 | -710.00M |
| June 30, 2024 | -307.00M |
| March 31, 2024 | -2.207B |
| December 31, 2023 | -727.00M |
| September 30, 2023 | -229.00M |
| June 30, 2023 | -483.00M |
| March 31, 2023 | -826.00M |
| December 31, 2022 | -375.00M |
| September 30, 2022 | -713.00M |
| June 30, 2022 | -308.00M |
| March 31, 2022 | -1.07B |
| December 31, 2021 | -278.00M |
| September 30, 2021 | -234.00M |
| June 30, 2021 | -577.00M |
| March 31, 2021 | -2.042B |
| December 31, 2020 | -8.977B |
| September 30, 2020 | -271.00M |
| Date | Value |
|---|---|
| June 30, 2020 | -5.023B |
| March 31, 2020 | -344.00M |
| December 31, 2019 | 431.00M |
| September 30, 2019 | -2.095B |
| June 30, 2019 | -6.042B |
| March 31, 2019 | -111.00M |
| December 31, 2018 | 2.735B |
| September 30, 2018 | 2.025B |
| June 30, 2018 | 5.241B |
| March 31, 2018 | 4.354B |
| December 31, 2017 | -10.02B |
| September 30, 2017 | -2.114B |
| June 30, 2017 | -4.246B |
| March 31, 2017 | 307.00M |
| December 31, 2016 | -2.675B |
| September 30, 2016 | -3.917B |
| June 30, 2016 | -3.284B |
| March 31, 2016 | -2.109B |
| December 31, 2015 | -2.438B |
| September 30, 2015 | -4.186B |
| June 30, 2015 | -3.552B |
| March 31, 2015 | -2.299B |
| December 31, 2014 | -404.76M |
| September 30, 2014 | -770.05M |
| June 30, 2014 | -487.25M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | -288.10M |
| AbbVie, Inc. | -10.22B |
| Biogen, Inc. | -222.10M |
| Vertex Pharmaceuticals, Inc. | -6.101B |
| Amgen, Inc. | -649.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 5.035B |
| Cash from Financing (Quarterly) | -1.528B |
| Free Cash Flow | 13.78B |
| Free Cash Flow Per Share (Quarterly) | 3.835 |
| Free Cash Flow to Equity (Quarterly) | 4.813B |
| Free Cash Flow to Firm (Quarterly) | 5.011B |
| Free Cash Flow Yield | 6.60% |